Skip to main content

Table 3 Comparing clinical and laboratory data of the patients at diagnosis (first assessment) and after 3 years (second assessment)

From: COL1A1 polymorphism and neurological complications in pediatric acute lymphoblastic leukemia patients and their associations with altered bone mineral density

 

Acute lymphoblastic leukemia patients

p value

First assessment

Second assessment

BMI percentile

84th (70th–90th)

86th (75th–91th)

0.1

Neurological complications

–

seizures (4%), peripheral neuropathy (10%), lumbosacral radiculopathy (10%)

–

Fracture detection

–

7 (7%)*

–

BMDLS

− 1.9 Âħ 0.44

− 2.654 Âħ 0.11*

0.01*

Parathormon (ng/l)

45 (10–56)

49 (12–60)

0.8

Total calcium (mg/dl)

9 Âħ 0.9

10.8 Âħ 0.20

0.2

Vitamin D (nmol/l)

44 (6–59)

40(12–55)

0.2

Osteocalcin (ng/ml)

18 (9–23)

13 (–20)*

0.01*

Alkaline phosphatase (U/L)

99 (60–135)*

75 (4–88)*

0.04*

  1. BMDLS bone mineral density of lumbar spine, PTH parathormon, OC osteocalcin, ALP alkaline phosphatase
  2. *Significant